The Cooley’s Anemia Foundation (CAF) recognizes the importance of maintaining health among thalassemia patients and is offering reimbursement of up to $500 for approved expenses related to health maintenance among U.S. thalassemia patients who are age 50 or older.
The Cooley’s Anemia Foundation (CAF) offers travel support to treatment centers to Thalassemia patients. We’re offering limited financial assistance to individuals with thalassemia who experience financial hardship due to travel expenses incurred in obtaining an annual comprehensive care evaluation or extraordinary thalassemia care at a major treatment center.
We’re proud to announce two new Cooley’s Anemia Foundation Medical Research Fellowships and two renewal Medical Research Fellowships for the 2023-2024 grant cycle. The total amount of funding for the two research Fellowships is $200,000. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic accomplishments and future […]
The council will bring together patients, caregivers and physicians from these communities, which share commonalities in underlying disease pathology, difficulties in transitioning from pediatric to adult care and quality of life concerns.
The Cooley’s Anemia Foundation’s Westchester-Rockland Chapter welcomes all to experience its 25th annual “Night at the Races” benefit on April 1, 2023.
The Centers for Disease Control and Prevention (CDC) recently launched a Thalassemia Healthcare Provider Resource Toolkit.
Did you know high levels of social support are linked to improved health outcomes in people with chronic health conditions? Join a virtual support group today!
Are you or a loved one considering gene therapy as a treatment option for transfusion dependent beta thalassemia? Watch the recording of the Gene Therapy Webinar featuring Dr. Sujit Sheth and reps from bluebird bio now!
When Maybelline, the iconic beauty brand behind Maria’s first blush, invited her to star in their “We Speak” disability pride campaign, she seized the opportunity to become the very thing she longed to see as a child—a model proudly representing the thalassemia community.
bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
